MIRA PHARMACEUTICALS INC

Company Overview

MIRA Pharmaceuticals is a clinical-stage, neuroscience-focused biopharma developing two oral small-molecule programs: Ketamir‑2 (a ketamine analog in Phase I/IND-enabled for neuropathic pain with potential CNS indications) and MIRA‑55 (a preclinical CB2‑preferring cannabinoid analog). The company is asset‑light and development‑focused (five part‑time employees, contractors, CRO/CDMO partners) with exclusive North American licenses for its lead assets and a history of using external vendors for IND‑enabling work and trials. Recent operational milestones include FDA IND clearance for U.S. studies, ongoing Phase I cohorts, and a DEA finding that neither candidate will be scheduled as controlled substances—reducing a key commercialization barrier. Financially MIRA is cash‑constrained (cash runway currently into Q4 2025 per filings), pursuing financing options including ATM sales and a contemplated SKNY acquisition to shore up capital.

Executive Compensation Practices

Filings show the company records and increasingly relies on stock‑based compensation (measured under ASC 718), and reported higher stock‑based expense in early 2025; this implies executives and key employees are materially paid with equity rather than cash. Given the firm’s limited cash runway and small headcount, compensation is likely weighted toward equity grants, option awards and milestone/retention incentives tied to IND/clinical progress, regulatory clearances, partnering or successful financing/transactions. Expect pay designs common in small biotech: modest cash salaries, time‑ and performance‑vested equity, and potential deal‑related earnouts or transaction bonuses (e.g., for licensing or M&A) to conserve cash and align management with value‑creating clinical milestones. Increased noncash stock compensation inflates reported G&A volatility and creates potential dilution when options vest/exercise, which investors should monitor.

Insider Trading Considerations

MIRA’s small float, early‑stage binary catalysts (trial cohorts, IND milestones, neurotoxicity study completion, SKNY merger/financing), and capital raises (ATM/block sales noted in filings) make insider trades potentially high‑signal but also high‑impact on stock price. Insider purchases could signal confidence in imminent clinical or financing catalysts, while insider sales may reflect cash needs, option exercises, or routine liquidity following equity grants—so context (timing relative to financing, vesting, or Section 10b5‑1 plans) is critical. As a reporting company, insider trades are subject to SEC reporting (Forms 3/4/5 and Section 16 rules) and likely internal blackout periods around material nonpublic clinical data and transaction negotiations; additionally, Nasdaq compliance/remediation events and potential transaction consideration (SKNY) can influence both the timing and interpretation of insider activity.